Subcutaneous immunotherapy in patients with eosinophilic esophagitis

Allergy - 2d ago Preview

 
 
• AUTO POST
 
• SAVE TO EVERNOTE

Publication date: May 2019

Source: Annals of Allergy, Asthma & Immunology, Volume 122, Issue 5

Author(s): Benjamin S. Robey, Swathi Eluri, Craig C. Reed, Maya R. Jerath, Michelle L. Hernandez, Scott P. Commins, Evan S. Dellon

Potential competing interests

Dr. Dellon is a consultant for Adare, Alivio, Allakos, Banner, Calypso, Enumeral, EsoCap, GSK, Gossamer Bio, Receptos/Celegene, Regeneron, Robarts, and Shire, receives research funding from Allakos, Adare, GSK, Meritage, Miraca, Nutricia, Receptos/Celgene, Regeneron, and Shire, and has received an educational grant from Allakos, Banner, and Holoclara. None of the other authors report and potential conflicts of interest with this study.

Funding Source

This study was funded in part by NIH award T32 DK007634 (SE; CCR). It also used services from the NC Translational and Clinical Sciences (NC TraCS) Institute, which is supported by the National Center for Advancing Translational Sciences (NCATS) through Grant Award Number UL1TR002489.